Clinical Scorecard: Distribution of Pneumococcal Serotypes and Evaluation of Current and Upcoming Pneumococcal Vaccines' Coverage
At a Glance
Category
Detail
Condition
Invasive pneumococcal disease (IPD) and pneumococcal acute respiratory infections (ARIs) including acute otitis media (AOM), sinusitis, and nonbacteremic pneumonia
Key Mechanisms
Pneumococcal conjugate vaccines (PCVs) target specific pneumococcal serotypes to reduce colonization and disease; vaccine-induced serotype pressure leads to shifts in circulating serotypes requiring vaccine reformulation
Target Population
Children and adults in the United States
Care Setting
Outpatient and inpatient settings managing ARIs, pneumonia hospitalizations, and invasive pneumococcal disease
Key Highlights
PCV serotype coverage varies by vaccine valency: PCV15 covers 16%–43%, PCV20 covers up to 52%, PCV21 up to 69%, and PCV31 up to 87% of pneumococcal disease burden depending on syndrome and age group
Pneumococcal ARIs and IPD burdens potentially preventable by PCVs include 270,000–3,300,000 outpatient ARIs, 2,000–17,000 pneumonia hospitalizations, and 3,000–14,000 IPD cases annually in the US
Current ACIP recommendations include PCV15 and PCV20 for infants and PCV21, PCV20, or PCV15 plus PPSV23 for adults ≥50 years or adults 19–49 years with certain conditions; pipeline vaccines (PCV24, PCV25, PCV31) may expand coverage
Guideline-Based Recommendations
Diagnosis
Diagnosis of pneumococcal disease includes identification of invasive pneumococcal disease (bacteremia, meningitis, bacteremic pneumonia) and noninvasive ARIs (AOM, sinusitis, nonbacteremic pneumonia)
Serotype distribution is assessed via population and laboratory surveillance to inform vaccine formulation
Management
Vaccination with PCVs is recommended to reduce vaccine-serotype colonization and disease burden
Current ACIP recommendations endorse PCV15 and PCV20 for infants and PCV21, PCV20, or PCV15 plus PPSV23 for adults ≥50 years and certain adults 19–49 years
Pipeline vaccines (PCV24, PCV25, PCV31) are under clinical evaluation to broaden serotype coverage
Monitoring & Follow-up
Ongoing surveillance of pneumococcal serotype distribution in IPD and ARIs is essential to detect shifts in serotype prevalence due to vaccine pressure
Monitoring vaccine effectiveness and disease incidence informs policy and vaccine reformulation
Risks
Vaccine-induced pressure on targeted serotypes can lead to increased circulation of non-vaccine serotypes
Incomplete serotype coverage by current vaccines may leave residual disease burden
Patient & Prescribing Data
Children and adults in the United States at risk for pneumococcal disease
Higher-valency PCVs (e.g., PCV31) potentially prevent a larger proportion of pneumococcal disease cases compared to lower-valency vaccines; vaccine choice should consider serotype coverage and patient age/condition
Clinical Best Practices
Use population-based serotype surveillance data to guide vaccine selection and policy decisions
Implement ACIP-recommended PCV vaccination schedules for infants and adults at risk
Consider emerging higher-valency PCVs as they become available to expand pneumococcal disease prevention
Maintain vigilance for serotype replacement and adjust vaccination strategies accordingly
by Laura M King, Kristin L Andrejko, Miwako Kobayashi, Wei Xing, Adam L Cohen, Wesley H Self, J Jackson Resser, Cynthia G Whitney, Adrienne Baughman, Mai Kio, Carlos G Grijalva, Jessica Traenkner, Nadine Rouphael, Joseph A Lewnard
